<?xml version="1.0" encoding="UTF-8"?><xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:f="http://xbrl.dcca.dk/sob" xmlns:b="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature" xmlns:h="http://xbrl.dcca.dk/mrv" xmlns:g="http://xbrl.dcca.dk/arr" xmlns:d="http://xbrl.dcca.dk/cmn" xmlns:e="http://xbrl.dcca.dk/fsa" xmlns:c="http://xbrl.dcca.dk/gsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature http://archprod.service.eogs.dk/taxonomy/20161001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20161001.xsd"><link:schemaRef xlink:type="simple" xlink:href="http://archprod.service.eogs.dk/taxonomy/20161001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20161001.xsd"/><c:InformationOnTypeOfSubmittedReport contextRef="c1">Årsrapport</c:InformationOnTypeOfSubmittedReport><c:IdentificationNumberCvrOfSubmittingEnterprise contextRef="c1">33771231</c:IdentificationNumberCvrOfSubmittingEnterprise><c:NameOfSubmittingEnterprise contextRef="c1">PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab</c:NameOfSubmittingEnterprise><c:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="c1">Strandvejen 44</c:AddressOfSubmittingEnterpriseStreetAndNumber><c:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="c1">2900 Hellerup</c:AddressOfSubmittingEnterprisePostcodeAndTown><c:ReportingPeriodStartDate contextRef="c1">2017-01-01</c:ReportingPeriodStartDate><c:PrecedingReportingPeriodStartDate contextRef="c1">2016-01-01</c:PrecedingReportingPeriodStartDate><c:ReportingPeriodEndDate contextRef="c1">2017-12-31</c:ReportingPeriodEndDate><c:PredingReportingPeriodEndDate contextRef="c1">2016-12-31</c:PredingReportingPeriodEndDate><c:IdentificationNumberCvrOfReportingEntity contextRef="c1">32272452</c:IdentificationNumberCvrOfReportingEntity><c:NameOfReportingEntity contextRef="c1">Danish BioVenture General Partner ApS</c:NameOfReportingEntity><c:AddressOfReportingEntityStreetName contextRef="c1">Axeltorv</c:AddressOfReportingEntityStreetName><c:AddressOfReportingEntityStreetBuildingIdentifier contextRef="c1">2</c:AddressOfReportingEntityStreetBuildingIdentifier><c:AddressOfReportingEntityPostCodeIdentifier contextRef="c1">1609</c:AddressOfReportingEntityPostCodeIdentifier><c:AddressOfReportingEntityDistrictName contextRef="c1">København V</c:AddressOfReportingEntityDistrictName><c:RegisteredOfficeOfReportingEntity contextRef="c1">København V</c:RegisteredOfficeOfReportingEntity><d:NameOfAuditFirm contextRef="c93">PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab</d:NameOfAuditFirm><d:IdentificationNumberCvrOfAuditFirm contextRef="c93">33771231</d:IdentificationNumberCvrOfAuditFirm><c:AddressOfAuditorStreetName contextRef="c93">Ndr. Ringgade</c:AddressOfAuditorStreetName><c:AddressOfAuditorStreetBuildingIdentifier contextRef="c93">70C</c:AddressOfAuditorStreetBuildingIdentifier><c:AddressOfAuditorPostCodeIdentifier contextRef="c93">4200</c:AddressOfAuditorPostCodeIdentifier><c:AddressOfAuditorDistrictName contextRef="c93">Slagelse</c:AddressOfAuditorDistrictName><c:AddressOfAuditorCountry contextRef="c1">Danmark</c:AddressOfAuditorCountry><c:DateOfGeneralMeeting contextRef="c1">2018-06-13</c:DateOfGeneralMeeting><c:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="c1">Tomas Haagen</c:NameAndSurnameOfChairmanOfGeneralMeeting><e:ClassOfReportingEntity contextRef="c1">Regnskabsklasse B</e:ClassOfReportingEntity><e:SelectedElementsFromReportingClassC contextRef="c1">1</e:SelectedElementsFromReportingClassC><d:TypeOfAuditorAssistance contextRef="c1">Andre erklæringer uden sikkerhed</d:TypeOfAuditorAssistance><f:IdentificationOfApprovedAnnualReport contextRef="c1" xml:lang="da">Direktionen har dags dato behandlet og godkendt årsrapporten for regnskabsåret 1. januar - 31. december 2017 for Danish BioVenture General Partner ApS.</f:IdentificationOfApprovedAnnualReport><f:IdentificationOfApprovedAnnualReport contextRef="c1" xml:lang="en">The Executive Board has today considered and adopted the Annual Report of Danish BioVenture General Partner ApS for the financial year 1 January - 31 December 2017.</f:IdentificationOfApprovedAnnualReport><f:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="c1" xml:lang="da">Årsrapporten er aflagt i overensstemmelse med årsregnskabsloven. Selskabet opfylder betingelserne for at undlade at lade årsregnskabet revidere.</f:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement><f:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="c1" xml:lang="en">The Annual Report is prepared in accordance with the Danish Financial Statements Act. The Company complies with the exemption provisions governing the omission to have its Financial Statements audited.</f:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement><f:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="c1" xml:lang="da">Årsregnskabet giver efter vores opfattelse et retvisende billede af selskabets aktiver, passiver og finansielle stilling pr. 31. december 2017 samt af resultatet af selskabets aktiviteter for 2017.</f:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults><f:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="c1" xml:lang="en">In our opinion the Financial Statements give a true and fair view of the financial position at 31 December 2017 of the Company and of the results of the Company operations for 2017.</f:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults><f:ManagementsStatementAboutManagementsReview contextRef="c1" xml:lang="da">Ledelsesberetningen indeholder efter vores opfattelse en retvisende redegørelse for de forhold, beretningen omhandler.</f:ManagementsStatementAboutManagementsReview><f:ManagementsStatementAboutManagementsReview contextRef="c1" xml:lang="en">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review.</f:ManagementsStatementAboutManagementsReview><f:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="c1" xml:lang="da">Årsrapporten indstilles til generalforsamlingens godkendelse.</f:RecommendationForApprovalOfAnnualReportByGeneralMeeting><f:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="c1" xml:lang="en">We recommend that the Annual Report be adopted at the Annual General Meeting.</f:RecommendationForApprovalOfAnnualReportByGeneralMeeting><f:PlaceOfSignatureOfStatement contextRef="c1">København</f:PlaceOfSignatureOfStatement><f:DateOfApprovalOfAnnualReport contextRef="c1">2018-06-11</f:DateOfApprovalOfAnnualReport><g:SignatureOfAuditorsDate contextRef="c1">2018-06-11</g:SignatureOfAuditorsDate><d:NameAndSurnameOfMemberOfExecutiveBoard contextRef="c81">Otello Stampacchia</d:NameAndSurnameOfMemberOfExecutiveBoard><d:NameAndSurnameOfMemberOfExecutiveBoard contextRef="c82">Anne-Mari Paster</d:NameAndSurnameOfMemberOfExecutiveBoard><d:NameAndSurnameOfMemberOfExecutiveBoard contextRef="c83">Richard Lim</d:NameAndSurnameOfMemberOfExecutiveBoard><g:DescriptionOfOtherEngagement contextRef="c1" xml:lang="da">Til ledelsen i Danish BioVenture General Partner ApS
Vi har opstillet årsregnskabet for Danish BioVenture General Partner ApS for regnskabsåret 1. januar - 31. december 2017 på grundlag af selskabets bogføring og øvrige oplysninger, som De har tilvejebragt.

Årsregnskabet omfatter resultatopgørelse, balance, egenkapitalopgørelse og noter, herunder anvendt regnskabspraksis.

Vi har udført opgaven i overensstemmelse med ISRS 4410, Opgaver om opstilling af finansielle oplysninger.

Vi har anvendt vores faglige ekspertise til at assistere Dem med at udarbejde og præsentere årsregnskabet i overensstemmelse med årsregnskabsloven. Vi har overholdt relevante bestemmelser i revisorloven og FSR – danske revisorers Etiske regler for revisorer, herunder principper vedrørende integritet, objektivitet, faglig kompetence og fornøden omhu.

Årsregnskabet samt nøjagtigheden og fuldstændigheden af de oplysninger, der er anvendt til opstillingen af årsregnskabet, er Deres ansvar.

Da en opgave om opstilling af finansielle oplysninger ikke er en erklæringsopgave med sikkerhed, er vi ikke forpligtet til at verificere nøjagtigheden eller fuldstændigheden af de oplysninger, De har givet os til brug for at opstille årsregnskabet. Vi udtrykker derfor ingen revisions- eller reviewkonklusion om, hvorvidt årsregnskabet er udarbejdet i overensstemmelse med årsregnskabsloven.
</g:DescriptionOfOtherEngagement><g:DescriptionOfOtherEngagement contextRef="c1" xml:lang="en">To the Management of Danish BioVenture General Partner ApS
We have compiled the Financial Statements of Danish BioVenture General Partner ApS for the financial year 1 January - 31 December 2017 on the basis of the Enterprise’s accounting records and other information you have provided.

The Financial Statements comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.

We performed our work in accordance with ISRS 4410, Engagements to Compile Financial Information.

Based on our professional expertise, we have assisted you with the preparation and presentation of the Financial Statements in accordance with the Danish Financial Statements Act. We have complied with relevant provisions of the Danish Act on Approved Auditors and Audit Firms and FSR – Danish Auditors’ Code of Ethics, including the principles of integrity, objectivity, professional competence and due care.

The Financial Statements and the accuracy and completeness of the information forming the basis of the compilation of the Financial Statements are your responsibility.

As an engagement to compile financial information is not an assurance engagement, we are under no duty to verify the accuracy or completeness of the information you provided to us to compile the Financial Statements. Accordingly, we express no audit opinion or review opinion as to whether the Financial Statements have been prepared in accordance with the Danish Financial Statements Act.
</g:DescriptionOfOtherEngagement><g:SignatureOfAuditorsPlace contextRef="c1">Slagelse</g:SignatureOfAuditorsPlace><g:SignatureOfAuditorsDate contextRef="c1">2018-06-11</g:SignatureOfAuditorsDate><d:NameOfAuditFirm contextRef="c93">PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab</d:NameOfAuditFirm><d:NameAndSurnameOfAuditor contextRef="c93">Steen Lange</d:NameAndSurnameOfAuditor><d:DescriptionOfAuditor contextRef="c93">statsautoriseret revisor</d:DescriptionOfAuditor><d:IdentificationNumberOfAuditor contextRef="c93">mne19795</d:IdentificationNumberOfAuditor><h:ManagementsReview contextRef="c1" xml:lang="da">Årsrapporten for Danish BioVenture General Partner ApS for 2017 er udarbejdet i overensstemmelse med årsregnskabslovens bestemmelser for virksomheder i regnskabsklasse B med tilvalg af enkelte regler i klasse C.
Årsrapporten  er aflagt efter samme regnskabspraksis som sidste år.
Væsentligste aktiviteter
Selskabets formål er at være komplementar i K/S Danish BioVenture, (København) samt at udgøre ledelsen i og repræsentere K/S Danish BioVenture udadtil i forretningsmæssige sammenhænge. Selskabets formål er endvidere af forestå administration af og yde investeringsrådgivning til K/S Danish BioVenture, idet selskabet er berettiget til at delegere denne administration til tredjepart.
Udvikling i året
Selskabets resultatopgørelse for 2017 udviser et underskud på EUR 4.605, og selskabets balance pr. 31. december 2017 udviser en negativ egenkapital på EUR 38.624.
Usikkerhed ved indregning og måling
Der er ikke forekommet usikkerhed ved indregning og måling i årsrapporten.
Usædvanlige forhold
Selskabets aktiver, passiver og finansielle stilling pr. 31. december 2017 samt resultatet af selskabets aktiviteter for 2017 er ikke påvirket af usædvanlige forhold.
Begivenheder efter balancedagen
Der er ikke efter balancedagen indtruffet forhold, som har væsentlig indflydelse på bedømmelsen af årsrapporten.</h:ManagementsReview><h:ManagementsReview contextRef="c1" xml:lang="en">Financial Statements of Danish BioVenture General Partner ApS for 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B as well as selected rules applying to reporting class C.
The Annual Report has been prepared under the same accounting policies as last year.
Key activities
The object of the company shall be to act as general partner of K/S Danish BioVenture, (Copenhagen) and to constitute the management of and to represent K/S Danish Bioventure in external commercial relations. Further, the object of the company is to manage the administration of and render investment advice to/condut investment management in respekt of K/S Dansih BioVenture. The company is entitled to transfer its rights and obligations of said managment to third parties.
Development in the year
The income statement of the Company for 2017 shows a loss of EUR 4,605, and at 31 December 2017 the balance sheet of the Company shows negative equity of EUR 38,624.
Uncertainty relating to recognition and measurement
Recognition and measurement in the Annual Report have not been subject to any uncertainty.
Unusual events
The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.
Subsequent events
No events materially affecting the assessment of the Annual Report have occurred after the balance sheet date.</h:ManagementsReview><e:OtherOperatingIncome contextRef="c1" unitRef="u0" decimals="0">1679</e:OtherOperatingIncome><e:OtherOperatingIncome contextRef="c94" unitRef="u0" decimals="0">1679</e:OtherOperatingIncome><e:OtherExternalExpenses contextRef="c1" unitRef="u0" decimals="0">6284</e:OtherExternalExpenses><e:OtherExternalExpenses contextRef="c94" unitRef="u0" decimals="0">6836</e:OtherExternalExpenses><e:GrossResult contextRef="c1" unitRef="u0" decimals="0">-4605</e:GrossResult><e:GrossResult contextRef="c94" unitRef="u0" decimals="0">-5157</e:GrossResult><e:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="c1" unitRef="u0" decimals="0">-4605</e:ProfitLossFromOrdinaryActivitiesBeforeTax><e:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="c94" unitRef="u0" decimals="0">-5157</e:ProfitLossFromOrdinaryActivitiesBeforeTax><e:TaxExpense contextRef="c1" unitRef="u0" decimals="0">0</e:TaxExpense><e:TaxExpense contextRef="c94" unitRef="u0" decimals="0">0</e:TaxExpense><e:ProfitLoss contextRef="c1" unitRef="u0" decimals="0">-4605</e:ProfitLoss><e:ProfitLoss contextRef="c94" unitRef="u0" decimals="0">-5157</e:ProfitLoss><e:ProfitLoss contextRef="c109" unitRef="u0" decimals="0">-4605</e:ProfitLoss><e:ProfitLoss contextRef="c110" unitRef="u0" decimals="0">-5157</e:ProfitLoss><e:CashAndCashEquivalents contextRef="c112" unitRef="u0" decimals="0">0</e:CashAndCashEquivalents><e:CashAndCashEquivalents contextRef="c111" unitRef="u0" decimals="0">111</e:CashAndCashEquivalents><e:CurrentAssets contextRef="c112" unitRef="u0" decimals="0">0</e:CurrentAssets><e:CurrentAssets contextRef="c111" unitRef="u0" decimals="0">111</e:CurrentAssets><e:Assets contextRef="c112" unitRef="u0" decimals="0">0</e:Assets><e:Assets contextRef="c111" unitRef="u0" decimals="0">111</e:Assets><e:ContributedCapital contextRef="c112" unitRef="u0" decimals="0">16788</e:ContributedCapital><e:ContributedCapital contextRef="c111" unitRef="u0" decimals="0">16788</e:ContributedCapital><e:PaidContributedCapital contextRef="c112" unitRef="u0" decimals="0">16788</e:PaidContributedCapital><e:PaidContributedCapital contextRef="c111" unitRef="u0" decimals="0">16788</e:PaidContributedCapital><e:RetainedEarnings contextRef="c112" unitRef="u0" decimals="0">-55412</e:RetainedEarnings><e:RetainedEarnings contextRef="c111" unitRef="u0" decimals="0">-50808</e:RetainedEarnings><e:Equity contextRef="c112" unitRef="u0" decimals="0">-38624</e:Equity><e:Equity contextRef="c111" unitRef="u0" decimals="0">-34020</e:Equity><e:ShorttermTradePayables contextRef="c112" unitRef="u0" decimals="0">4500</e:ShorttermTradePayables><e:ShorttermTradePayables contextRef="c111" unitRef="u0" decimals="0">4500</e:ShorttermTradePayables><e:ShorttermPayablesToGroupEnterprises contextRef="c112" unitRef="u0" decimals="0">34124</e:ShorttermPayablesToGroupEnterprises><e:ShorttermPayablesToGroupEnterprises contextRef="c111" unitRef="u0" decimals="0">29631</e:ShorttermPayablesToGroupEnterprises><e:ShorttermLiabilitiesOtherThanProvisions contextRef="c112" unitRef="u0" decimals="0">38624</e:ShorttermLiabilitiesOtherThanProvisions><e:ShorttermLiabilitiesOtherThanProvisions contextRef="c111" unitRef="u0" decimals="0">34131</e:ShorttermLiabilitiesOtherThanProvisions><e:LiabilitiesOtherThanProvisions contextRef="c112" unitRef="u0" decimals="0">38624</e:LiabilitiesOtherThanProvisions><e:LiabilitiesOtherThanProvisions contextRef="c111" unitRef="u0" decimals="0">34131</e:LiabilitiesOtherThanProvisions><e:LiabilitiesAndEquity contextRef="c112" unitRef="u0" decimals="0">0</e:LiabilitiesAndEquity><e:LiabilitiesAndEquity contextRef="c111" unitRef="u0" decimals="0">111</e:LiabilitiesAndEquity><e:Equity contextRef="c2" unitRef="u0" decimals="0">16788</e:Equity><e:Equity contextRef="c22" unitRef="u0" decimals="0">-50807</e:Equity><e:ProfitLoss contextRef="c23" unitRef="u0" decimals="0">-4605</e:ProfitLoss><e:Equity contextRef="c4" unitRef="u0" decimals="0">16788</e:Equity><e:Equity contextRef="c24" unitRef="u0" decimals="0">-55412</e:Equity><e:DisclosureOfUncertaintiesRelatingToGoingConcern contextRef="c1" xml:lang="da">Selskabet har tabt kapitalen og er omfattet af kapitaltabsreglerne i Selskabsloven. Der er indhentet støtteerklæring fra Omega Fund management Limited, Guernsey om finansiel støtte og på baggrund heraf aflægges regnskabet under forudsætning om fortsat drift.</e:DisclosureOfUncertaintiesRelatingToGoingConcern><e:DisclosureOfUncertaintiesRelatingToGoingConcern contextRef="c1" xml:lang="en">The Company has lost its capital and is comprised by the capital loss rules of the Danish Companies Act. A letter of support has been obtained from Omega Fund Management Limited, Guernsey, with respect to financial support and based on this the Financial Statements are prepared under a going concern assumption.</e:DisclosureOfUncertaintiesRelatingToGoingConcern><e:DisclosureOfContingentLiabilities contextRef="c1" xml:lang="da">Eventualforpligtelser
Selskabet er komplementar i K/S Danish Bioventure og hæfter derved for al gæld i K/S'et. Herudover er der ikke sikkerhedsstillelser og eventualforpligtelser pr. 31. december 2017.</e:DisclosureOfContingentLiabilities><e:DisclosureOfContingentLiabilities contextRef="c1" xml:lang="en">Contingent liabilities
The Company is a general partner in K/S Danish Bio venture and thus liable for all debts of the limited partnership. Other than that, there are no provision of security and contingent liabilities at 31 December 2017.</e:DisclosureOfContingentLiabilities><e:InformationOnReportingClassOfEntity contextRef="c1" xml:lang="da">Årsrapporten for Danish BioVenture General Partner ApS for 2017 er udarbejdet i overensstemmelse med årsregnskabslovens bestemmelser for virksomheder i regnskabsklasse B med tilvalg af enkelte regler i klasse C.
Den anvendte regnskabspraksis er uændret i forhold til sidste år.
Årsregnskab for 2017 er aflagt i EUR.</e:InformationOnReportingClassOfEntity><e:InformationOnReportingClassOfEntity contextRef="c1" xml:lang="en">The Annual Report of Danish BioVenture General Partner ApS for 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B as well as selected rules applying to reporting class C.
The accounting policies applied remain unchanged from last year.
The Financial Statements for 2017 are presented in EUR.</e:InformationOnReportingClassOfEntity><e:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies contextRef="c1" xml:lang="da">Indtægter indregnes i resultatopgørelsen i takt med, at de indtjenes. Herudover indregnes værdireguleringer af finansielle aktiver og forpligtelser, der måles til dagsværdi eller amortiseret kostpris. Endvidere indregnes i resultatopgørelsen alle omkostninger, der er afholdt for at opnå årets indtjening, herunder afskrivninger, nedskrivninger og hensatte forpligtelser samt tilbageførsler som følge af ændrede regnskabsmæssige skøn af beløb, der tidligere har været indregnet i resultatopgørelsen.
Aktiver indregnes i balancen, når det er sandsynligt, at fremtidige økonomiske fordele vil tilflyde selskabet, og aktivets værdi kan måles pålideligt.
Forpligtelser indregnes i balancen, når det er sandsynligt, at fremtidige økonomiske fordele vil fragå selskabet, og forpligtelsens værdi kan måles pålideligt.
Ved første indregning måles aktiver og forpligtelser til kostpris. Efterfølgende måles aktiver og forpligtelser som beskrevet for hver enkelt regnskabspost nedenfor.</e:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies><e:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies contextRef="c1" xml:lang="en">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised cost are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.
Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.
Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.
Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</e:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies><e:DescriptionOfMethodsOfForeignCurrencies contextRef="c1" xml:lang="da">Transaktioner i fremmed valuta omregnes til transaktionsdagens kurs. Valutakursdifferencer, der opstår mellem transaktionsdagens kurs og kursen på betalingsdagen, indregnes i resultatopgørelsen som en finansiel post. Hvis valutapositioner anses for sikring af fremtidige pengestrømme, indregnes værdireguleringerne direkte på egenkapitalen.
Tilgodehavender, gæld og andre monetære poster i fremmed valuta, som ikke er afregnet på balancedagen, måles til balancedagens valutakurs. Forskellen mellem balancedagens kurs og kursen på tidspunktet for tilgodehavendets eller gældens opståen indregnes i resultatopgørelsen under finansielle indtægter og omkostninger.</e:DescriptionOfMethodsOfForeignCurrencies><e:DescriptionOfMethodsOfForeignCurrencies contextRef="c1" xml:lang="en">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Exchange differences arising due to differences between the transaction date rates and the rates at the dates of payment are recognised in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognised directly in equity.
Receivables, payables and other monetary items in foreign currencies that have not been settled at the balance sheet date are translated at the exchange rates at the balance sheet date. Any differences between the exchange rates at the balance sheet date and the rates at the time when the receivable or the debt arose are recognised in financial income and expenses in the income statement.</e:DescriptionOfMethodsOfForeignCurrencies><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="c1" xml:lang="da">Andre eksterne omkostninger indeholder omkostninger til lokaler, salg og distribution samt kontorhold mv.</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="c1" xml:lang="en">Other external expenses comprise expenses for premises, sales and distribution as well as office expenses, etc.</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncomeAndExpenses contextRef="c1" xml:lang="da">Andre driftsindtægter og andre driftsomkostninger omfatter regnskabsposter af sekundær karakter i forhold til selskabets hovedaktivitet.</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncomeAndExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncomeAndExpenses contextRef="c1" xml:lang="en">Other operating income and other operating expenses comprise items of a secondary nature to the main activities of the Company.</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncomeAndExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="c1" xml:lang="da">Skat af årets resultat består af årets aktuelle skat og forskydning i udskudt skat og indregnes i resultatopgørelsen med den del, der kan henføres til årets resultat, og direkte på egenkapitalen med den del, der kan henføres til posteringer direkte på egenkapitalen.</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="c1" xml:lang="en">Tax for the year consists of current tax for the year and changes in deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity transactions is recognised directly in equity.</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="c1" xml:lang="da">Gældsforpligtelser måles til amortiseret kostpris, der i al væsentlighed svarer til nominel værdi.</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="c1" xml:lang="en">Debts are measured at amortised cost, substantially corresponding to nominal value.</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions><!--Aktuelle periode enkelt selskab--><context id="c1"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><startDate>2017-01-01</startDate><endDate>2017-12-31</endDate></period></context><!--Virksomhedskapital aktuel primo--><context id="c2"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><instant>2017-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital aktuel ultimo--><context id="c4"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><instant>2017-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel primo--><context id="c22"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><instant>2017-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel i aaret--><context id="c23"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><startDate>2017-01-01</startDate><endDate>2017-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel ultimo--><context id="c24"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><instant>2017-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--CEO1--><context id="c81"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><startDate>2017-01-01</startDate><endDate>2017-12-31</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfMemberOfExecutiveBoardDimension"><d:memberOfBoardIdentifier>1</d:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--CEO2--><context id="c82"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><startDate>2017-01-01</startDate><endDate>2017-12-31</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfMemberOfExecutiveBoardDimension"><d:memberOfBoardIdentifier>2</d:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--CEO3--><context id="c83"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><startDate>2017-01-01</startDate><endDate>2017-12-31</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfMemberOfExecutiveBoardDimension"><d:memberOfBoardIdentifier>3</d:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--REVISOR1--><context id="c93"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><startDate>2017-01-01</startDate><endDate>2017-12-31</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfAuditorDimension"><d:auditorIdentifier>1</d:auditorIdentifier></xbrldi:typedMember></scenario></context><!--Forrige periode enkelt selskab--><context id="c94"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><startDate>2016-01-01</startDate><endDate>2016-12-31</endDate></period></context><!--Overfoert resultat aktuel i aaret--><context id="c109"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><startDate>2017-01-01</startDate><endDate>2017-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ResultDistributionDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfoert resultat forrige i aaret--><context id="c110"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><startDate>2016-01-01</startDate><endDate>2016-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ResultDistributionDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Slutdato forrige periode enkelt selskab--><context id="c111"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><instant>2016-12-31</instant></period></context><!--Slutdato aktuelle periode enkelt selskab--><context id="c112"><entity><identifier scheme="http://www.dcca.dk/cvr">32272452</identifier></entity><period><instant>2017-12-31</instant></period></context><!--DKK enere--><unit id="u0"><measure>iso4217:EUR</measure></unit></xbrl>